- DokumenOMCIJ.MS.ID.555853diunggah oleh
Drkrishnasarma pathy
- DokumenPatent Evaluation on Monoclonal Antibody (MAB) Therapy with Binding Specificity to CD20 B-Cell Surface Antigen Bp35 and the Manufacturing Process of Biological &Antibodies and Derivativesdiunggah oleh
Drkrishnasarma pathy
- DokumenInternational Journal of Research Studies in Medical and Health Sciences-Antiviral nucleosides- Flu Viruses- QUINOLINES-COVID-19 Dr Krishna sarma pathydiunggah oleh
Drkrishnasarma pathy
- DokumenHCV NS3/4A 3 Protease Inhibitorsdiunggah oleh
Drkrishnasarma pathy
- DokumenBJSTR.MS.ID.003667 Chronic Hepatitis (Chc), Viral Polymerase Nucleotide Inhibitor & Process Patents Review and Evaluation, Preparation of Sofosbuvirdiunggah oleh
Drkrishnasarma pathy
- DokumenLOJMS.MS.ID.000121 An anti-inflammatory adrenocorticalsteroid Hydrocortisonesodiumsuccinate, hydrocortisone preparation and validated for the confirmation/ determination and quantification of hydrocortisonediunggah oleh
Drkrishnasarma pathy
- DokumenAn Anti-Inflammatory Adrenocorticalsteroid Hydrocortisonesodiumsuccinate, Hydrocortisone Preparation and Validated for the Confirmation Determination and Quantification of Hydrocortisonediunggah oleh
Drkrishnasarma pathy
- Dokumenlojdiunggah oleh
Drkrishnasarma pathy
- Dokumenconsiderationsdiunggah oleh
Drkrishnasarma pathy
- Dokumencefpodoximediunggah oleh
Drkrishnasarma pathy
- Dokumenlojdiunggah oleh
Drkrishnasarma pathy
- Dokumenbjstr.ms.id.001662considerationsdiunggah oleh
Drkrishnasarma pathy
- Dokumenconsiderationsdiunggah oleh
Drkrishnasarma pathy
- Dokumenbjstr.ms.id.001662considerationsdiunggah oleh
Drkrishnasarma pathy
- DokumenJOJS.MS.ID.555566 (1)Case History-The Control of Impurities-A Critical Issue to The Active Pharmaceutical Ingredientdiunggah oleh
Drkrishnasarma pathy
- DokumenCase History-The Control of Impurities-A Critical Issue to The Active Pharmaceutical Ingredient JOJ Scin 1(4) JOJS.ms.ID.555566 (2018) Krishnasarmapathydiunggah oleh
Drkrishnasarma pathy
- DokumenKrishnasarma Pathy K (2018) Entecavir Patent Evaluation & Genotoxicitydiunggah oleh
Drkrishnasarma pathy
- DokumenHerald Scholarly Open AccessPathy K (2018) Entecavir Patent Evaluation & Genotoxicity. J Toxicol Cur Res 2 005.diunggah oleh
Drkrishnasarma pathy
- DokumenKrishnasarma Pathy K (2018) Entecavir Patent Evaluation & Genotoxicitydiunggah oleh
Drkrishnasarma pathy
- DokumenJPP-18-RA-1899-Entecavir-patent-evaluation--method--for-diastereomeric-Impurities--/1899diunggah oleh
Drkrishnasarma pathy
- DokumenHttpswww.ommegaonline.orgarticle Details Entecavir Patent Evaluation Method for Diastereomeric Impurities 1899diunggah oleh
Drkrishnasarma pathy
- DokumenEntecavir Patent Evaluation, Method for Diastereomeric Impurities OMCIJ.MS.ID.555711diunggah oleh
Drkrishnasarma pathy
- DokumenPreparation of Vitamin C and Method for Determination of Vitamin C in Tablets SCSOAJ.ms.ID.000114diunggah oleh
Drkrishnasarma pathy
- DokumenRoute Evaluation and Analytical HPLC Method Development of Buprenorphine, Naloxone, And Comparison OverallSJFN.ms.ID.000105diunggah oleh
Drkrishnasarma pathy
- DokumenOMCIJ.MS.ID.555674 .diunggah oleh
Drkrishnasarma pathy
- DokumenSRMRCR-01-00014 (1)diunggah oleh
Drkrishnasarma pathy
- DokumenOAJT.ms.ID.555593 Krishnasarmapathydiunggah oleh
Drkrishnasarma pathy
- DokumenOAJT.ms.ID.555592krishnasarmapathydiunggah oleh
Drkrishnasarma pathy
- DokumenInt J clinical & case. 1:7, 140-144-The influenza A virus subtypes H1N1, H1N2 and H3N2 ,HDFxdiunggah oleh
Drkrishnasarma pathy
- DokumenThe influenza A virus subtypes H1N1, H1N2 and H3N2 ,HDFxdiunggah oleh
Drkrishnasarma pathy
- DokumenOAJT.MS.ID.555568 (1)Research Article Volume 1 Issue 4 - August 2017 DOIdiunggah oleh
Drkrishnasarma pathy
- DokumenOAJT.MS.ID.555568 (1)diunggah oleh
Drkrishnasarma pathy
- DokumenMethod Development and Pharmacological study of Chemotherapeutic Agents OAJT.ms.ID.555568 Drkrishnasarmapathydiunggah oleh
Drkrishnasarma pathy
- DokumenBASIC SKILLS TRAINING GUIDE -HPLC method development and validation- an overview Dr Sarma Krishna pathy ,YLN Murthy,Sunithasarma,Atchuutha ramaiahdiunggah oleh
Drkrishnasarma pathy
- DokumenBASIC SKILLS TRAINING GUIDE -HPLC Method Development and Validation- An Overview-1diunggah oleh
Drkrishnasarma pathy
- DokumenS- Amlo Besylatediunggah oleh
Drkrishnasarma pathy
- DokumenIndustrial process for OXICONAZOLE Dr krishnasarma Pathy step-I 2,2’4’-tri-choloroacetophenone,Imidazole reacted in presence of acetonitrile to form 1-(2,4-dichlorophenacyl)-imidazole (I).Which is then reacted with hydroxylamine. hydrochloride to give (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl) ethanone oxime (II). It is further reacted with 2,4-Dichlorobenzyl chloride in presence of sodium hydride to give (III) Oxiconazole and finally salt formation with nitric aciddiunggah oleh
Drkrishnasarma pathy
- DokumenArticlediunggah oleh
Drkrishnasarma pathy
- DokumenLab Notebook Example-Tris[(2-pyridyl)methyl]aminediunggah oleh
Drkrishnasarma pathy
- DokumenIPR - A Primer on Intellectual Property Rights-Dr KrishnasarmaPathydiunggah oleh
Drkrishnasarma pathy
- DokumenSolid-state Forms of Celecoxib and an Improved Process for the Preparation of Celecoxib Polymorphdiunggah oleh
Drkrishnasarma pathy
- DokumenCELECOXIBdiunggah oleh
Drkrishnasarma pathy
- DokumenIndustrial process for preparation of Levetiracetam.diunggah oleh
Drkrishnasarma pathy
- DokumenLevi Trace Tamdiunggah oleh
Drkrishnasarma pathy
- DokumenIndustrial process for preparation of Levetiracetam.diunggah oleh
Drkrishnasarma pathy
- DokumenLevi Trace Tamdiunggah oleh
Drkrishnasarma pathy
- DokumenVITAMIN Cdiunggah oleh
Drkrishnasarma pathy
- DokumenPHENYLEPHRINEdiunggah oleh
Drkrishnasarma pathy
- DokumenDEFINITION “IMPURITY”diunggah oleh
Drkrishnasarma pathy